VERU Veru Inc.

2.4
+0.01  (+0%)
Previous Close 2.4
Open 2.4
Price To Book 4.54
Market Cap 156,416,984
Shares 65,038,247
Volume 68,468
Short Ratio
Av. Daily Volume 132,652
Stock charts supplied by TradingView

NewsSee all news

  1. Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th

    MIAMI, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today

  2. Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

    -- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer

  3. Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

    MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today

  4. Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

    MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due January 2020.
Zuclomiphene citrate
Hot flashes
NDA filing due summer 2020.
Tadalafil and Finasteride combo
Benign prostatic hyperplasia (BPH)
Phase 2 trials to be initiated in 2020.
VERU-111 (bisindole)
Prostate cancer
Phase 2 trial to be initiated in 2020.
VERU-100
Prostate cancer

Latest News

  1. Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th

    MIAMI, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today

  2. Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

    -- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), The Prostate Cancer

  3. Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

    MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today

  4. Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

    MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today